Aztreonam lysine

Aztreonam lysine (29 Cayston ) Aztreonam (29) Monobactam antibiotic NP-deiived Microbial Antibacterial Inhibits bacterial cell wall synhiesis 312-318... 

McCoy KS, Quitmer AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. (2008) Inhaled aztreonam lysine for chronic airway Pseudomonas Aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 178 921-928. 

Retsch-Bogart GZ, Bums JL, Otto KL, Liou TG McCoy K, Oennann C, Gibson RL. (2008) A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas Aeruginosa infection. Pediatr Pulmonol 43 47-58. 

Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. (2009) Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 135 1223-1232. 

Plosker GL. Aztreonam lysine for inhalation solution in cystic fibrosis. Drugs 2010 70(14) 1843-55. 

Since that time, a significant number of variations on that theme have been placed into clinical trials and, in some cases, such as Aztreonam 28, into commerce. Recently (late 2007, early 2008), this compound was submitted for approval in the EU and the USA as the lysinate salt for the inhalation treatment of Pseudomonas aeruginosa in cystic fibrosis under an Orphan drug category. As of late 2008, the Food and Drug Administration (FDA) was requiring further information and the status of the EU application was not yet known. 

Drug formulations In February 2010, a solution of aztreonam for inhalation, formulated with lysine, was approved by the US FDA for the treatment of respiratory symptoms in patients with cystic fibrosis and infected with Pseudomonas aeruginosa [75 ], a bacterium that has always been difficult to treat with antibiotics, especially when it grows in biofilm, as is the case in the airways. So far, no new types of adverse effects have been found [76 ]. A key problem will be the development of resistance to this new formulation [77 ]. 

---